We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Merck & ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

We recently published a list of Billionaire Mario Gabelli’s 10 Large-Cap Stock Picks with Huge Upside Potential. In this ...

Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

The strong results of KEYNOTE-689 and likely FDA approval of pembrolizumab for perioperative HNSCC raise both concerns and ...

The Rutgers Institute for Corporate Social Innovation recognized leaders who demonstrate the potential for business to ...

The Dow Jones Industrial Average is trading down Tuesday afternoon with shares of Merck and Amgen seeing the biggest declines for the blue-chip average.

Behind losses for shares of Merck and Amgen, the Dow Jones Industrial Average is falling Tuesday afternoon.

Merck broke ground on a $1B, 470K SF biotech facility last month at the Chestnut Run Innovation & Science Park in Wilmington, ...

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...